Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals Stock
The Biocryst Pharmaceuticals stock is trending slightly upwards today, with an increase of €0.020 (0.330%) compared to yesterday's price.
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Biocryst Pharmaceuticals.
As a result the target price of 11 € shows a very positive potential of 84.63% compared to the current price of 5.96 € for Biocryst Pharmaceuticals.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Biocryst Pharmaceuticals stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Biocryst Pharmaceuticals | 0.330% | 5.339% | 49.736% | -22.884% | 7.662% | -54.010% | 90.351% |
Evolus Inc | - | 0.000% | 7.477% | 37.725% | 27.072% | 32.948% | - |
Ardelyx Inc. | 3.070% | 1.608% | 5.441% | 102.500% | 9.308% | 7.085% | - |
Salarius Pharmaceuticals Inc. | - | -3.015% | -6.311% | -66.724% | -30.450% | -98.501% | -99.994% |
Comments
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat